Emmaus Life Sciences annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Emmaus Life Sciences Gross Margin Growth & History (EMMA)
Emmaus Life Sciences's gross margin was 93.12% for fiscal 2025.
View full Emmaus Life Sciences company overviewEmmaus Life Sciences annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 93.12% | +0.33 pp |
| 2024 | 2024-12-31 | 92.79% | −2.68 pp |
| 2023 | 2023-12-31 | 95.47% | +9.54 pp |
| 2022 | 2022-12-31 | 85.93% | +2.00 pp |
| 2021 | 2021-12-31 | 83.93% | −6.37 pp |
| 2020 | 2020-12-31 | 90.30% | −4.90 pp |
| 2019 | 2019-12-31 | 95.19% | +58.09 pp |
| 2018 | 2018-09-30 | 37.10% | −21.26 pp |
| 2017 | 2017-09-30 | 58.37% | — |
Emmaus Life Sciences quarterly gross margin
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 94.56% | −0.12 pp |
| Q1 2026 | 2026-03-31 | 91.52% | +0.88 pp |
| Q4 2025 | 2025-12-31 | 93.90% | +3.29 pp |
| Q3 2025 | 2025-09-30 | 92.69% | −0.12 pp |
| Q2 2025 | 2025-06-30 | 94.68% | −0.84 pp |
| Q1 2025 | 2025-03-31 | 90.65% | +0.90 pp |
| Q4 2024 | 2024-12-31 | 90.61% | −6.68 pp |
| Q3 2024 | 2024-09-30 | 92.81% | −2.93 pp |
| Q2 2024 | 2024-06-30 | 95.52% | +0.24 pp |
| Q1 2024 | 2024-03-31 | 89.74% | −3.90 pp |
| Q4 2023 | 2023-12-31 | 97.30% | +8.17 pp |
| Q3 2023 | 2023-09-30 | 95.74% | +6.67 pp |
| Q2 2023 | 2023-06-30 | 95.28% | +4.52 pp |
| Q1 2023 | 2023-03-31 | 93.65% | +24.79 pp |
| Q4 2022 | 2022-12-31 | 89.12% | +55.38 pp |
| Q3 2022 | 2022-09-30 | 89.07% | −3.22 pp |
| Q2 2022 | 2022-06-30 | 90.76% | −2.61 pp |
| Q1 2022 | 2022-03-31 | 68.86% | −22.97 pp |
| Q4 2021 | 2021-12-31 | 33.74% | −52.82 pp |
| Q3 2021 | 2021-09-30 | 92.28% | +0.92 pp |
| Q2 2021 | 2021-06-30 | 93.37% | +3.60 pp |
| Q1 2021 | 2021-03-31 | 91.83% | −1.30 pp |
| Q4 2020 | 2020-12-31 | 86.56% | −8.68 pp |
| Q3 2020 | 2020-09-30 | 91.36% | −4.34 pp |
| Q2 2020 | 2020-06-30 | 89.77% | −5.42 pp |
| Q1 2020 | 2020-03-31 | 93.13% | −1.37 pp |
| Q4 2019 | 2019-12-31 | 95.24% | +53.39 pp |
| Q3 2019 · Sep 30 | 2019-09-30 | 95.69% | −1.42 pp |
| Q3 2019 · Jun 30 | 2019-06-30 | 95.19% | +57.54 pp |
| Q2 2019 | 2019-03-31 | 94.50% | +59.36 pp |
| Q1 2019 | 2018-12-31 | 41.85% | +11.44 pp |
| Q4 2018 | 2018-09-30 | 97.11% | — |
| Q3 2018 | 2018-06-30 | 37.66% | — |
| Q2 2018 | 2018-03-31 | 35.14% | — |
| Q1 2018 | 2017-12-31 | 30.41% | — |
Emmaus Life Sciences gross margin trends
Over the last five reported fiscal years, Emmaus Life Sciences's gross margin increased from 90.30% to 93.12%, a change of +2.82 percentage points. The latest reported quarter, Q2 2026, shows 94.56%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Emmaus Life Sciences filings at SEC.gov ↗